Tumor marker detection reagents are important tools for clinical diagnosis and monitoring of tumors. Their core function is to specifically identify tumor-related molecules, helping physicians assess disease progression or treatment efficacy. The main components of these reagents typically include antibodies, labels, buffer systems, and stabilizers, all of which work synergistically to ensure detection sensitivity and accuracy.
Antibodies, typically monoclonal or polyclonal, are key components of detection reagents and specifically bind to target tumor markers, such as alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), or prostate-specific antigen (PSA). The choice of antibody directly impacts the specificity of the assay; high-affinity antibodies can reduce false-positive results.
Labelers are used for signal amplification and visualization. Common examples include enzymes (such as horseradish peroxidase (HRP), fluorescent dyes (such as FITC), chemiluminescent substrates (such as luminol), or colloidal gold particles. For example, in enzyme-linked immunosorbent assays (ELISAs), HRP catalyzes the substrate to develop color, and the marker concentration is quantified by absorbance. Chemiluminescent immunoassays, on the other hand, rely on luminescence intensity to enhance detection sensitivity.
Buffer systems (such as phosphate buffered saline or Tris-HCl) maintain a stable pH in the reagent, ensuring an optimal environment for antibody and antigen binding. Furthermore, stabilizers (such as bovine serum albumin (BSA), glycerol, or preservatives) extend the reagent's shelf life and prevent protein denaturation and microbial contamination.
Some newer reagents also incorporate nanomaterials or biotin-streptavidin systems to further enhance detection efficiency. In summary, the design of tumor marker detection reagents requires a balanced balance of specificity, sensitivity, and stability to meet the needs of precision medicine.
